Outcome

This study demonstrates that Hyperbaric Oxygen Therapy (HBO) can effectively manage lipid metabolism dysfunction and obesity induced by a high-fat diet (HFD). Through a series of 30 sessions at 2.0 atmospheres absolute and 100% oxygen HBO significantly reduced body weight and fat deposition in HFD-fed C57/B6 mice.

Introduction

Obesity and metabolic syndrome often exacerbated by high-fat diets present significant health challenges worldwide. Recent research explores the potential of hyperbaric oxygen therapy (HBOT) to counteract the negative effects associated with these conditions. This study specifically investigates the therapeutic role of HBOT in addressing lipid metabolism dysfunction induced by high-fat diets with a focus on L-carnitine regulation. Utilizing C57/B6 mice the research involved 30 sessions of HBOT at 2.0 atmospheres absolute with 100% oxygen. The findings revealed notable improvements in the HBOT-treated mice such as reduced body weight and fat deposition normalized phosphorylation states of hormone-sensitive lipase (HSL) in adipose tissues and beneficial changes in L-carnitine levels and key metabolic protein expressions in skeletal muscle. These results suggest that HBOT holds promise as an effective treatment for managing obesity and metabolic disorders induced by high-fat diets.

Results

The study explored the impact of hyperbaric oxygen therapy (HBO) on obesity and metabolic syndrome induced by a high-fat diet (HFD) in C57/B6 mice. Mice were either maintained on a normal diet or a high-fat diet with some groups undergoing HBO therapy at 2.0 atmospheres absolute and 100% oxygen for 90 minutes per session five times a week for a total of 30 sessions.

Significant results included the following:

• Reduction in Body Weight and Fat Deposits: HBO therapy markedly reduced body weight and fat deposition in mice fed a high-fat diet compared to control groups.
• Normalization of Lipid Metabolism Markers: The phosphorylation state of hormone-sensitive lipase (HSL) vital for fat breakdown in adipose tissues was normalized in HBO-treated mice. Additionally HBO therapy normalized circulating levels of L-carnitine crucial for fat metabolism while increasing its concentration in skeletal muscle enhancing fat utilization and energy production in muscles.
• Restoration of Protein Expressions: There was a restoration in the expression levels of PPARα a key regulator of fat metabolism and a normalization of the expression of CPT1b involved in fat transport into mitochondria in skeletal muscles.
• Effects on Brown Adipose Tissue: HBO therapy reversed the increased expression of UCP1 and the phosphorylation of HSL caused by the high-fat diet in brown adipose tissue aiding in better fat metabolism.

Overall the study concluded that HBO therapy could effectively mitigate lipid metabolism dysfunction and alleviate obesity induced by a high-fat diet. The therapeutic benefits were associated with normalized levels of L-carnitine in skeletal muscle and the regulation of crucial proteins like PPARα and CPT1b that govern fat metabolism. These findings indicate that HBO therapy holds promise as a potential strategy to combat obesity and metabolic syndrome associated with high-fat diets.

Conclusion

In conclusion this study provides substantial evidence that Hyperbaric Oxygen Therapy (HBOT) can effectively address obesity and metabolic syndrome induced by a high-fat diet. Key findings include significant reductions in body weight and fat deposits as well as the normalization of lipid metabolism markers such as L-carnitine levels and the expression of critical proteins like PPARα and CPT1b in skeletal muscles. These outcomes underscore the therapeutic potential of HBOT in mitigating the adverse effects of high-fat diets particularly concerning lipid metabolism and energy utilization in muscle tissue.

The results of this investigation highlight the promise of HBOT as a viable intervention for managing obesity and its associated metabolic dysfunctions. Future research should explore the long-term effects of HBOT its application in human clinical trials and the mechanisms underpinning its beneficial outcomes. This study not only opens new avenues for the treatment of diet-induced metabolic disorders but also enhances our understanding of HBOT’s role in metabolic health.